Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived
Displaying 1 - 8 of 8 results

Growth Plate Injuries

https://www.niams.nih.gov/health-topics/growth-plate-injuries

What are growth plate injuries? The growth plate is the area of tissue near the ends of long bones in children and teens that determines what length and shape the bone will be once it is done growing. Each long bone— the thigh bone, the bones in the forearm, and the bones in the hands and fingers—has at least two growth plates, one at each end. Once your child has finished growing, the growth plates close and are replaced by solid bone. The growth plates are weak areas of your child’s growing skeleton, making it easier to injure them. Injuries

Sjögren’s Syndrome

https://www.niams.nih.gov/health-topics/sjogrens-syndrome

What is Sjögren’s syndrome? Sjögren’s syndrome is a chronic (long-lasting) disorder that happens when the immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body. The main symptoms are dry eyes and mouth, but the disorder may affect other parts of the body. Many people with Sjogren’s syndrome say they feel tired often (fatigue). They also may have joint and muscle pain. In addition, the disease can damage the lungs, kidneys, and nervous system.

Giant Cell Arteritis

https://www.niams.nih.gov/health-topics/giant-cell-arteritis

What is giant cell arteritis? Giant cell arteritis causes the arteries of the scalp and neck to become red, hot, swollen, or painful. The arteries most affected are those in the temples on either side of the head. These arteries narrow, so not enough blood can pass through. It is important that you get treatment right away. Otherwise, the arteries could be permanently damaged. There is also a risk of blindness or stroke. If you have giant cell arteritis, your doctor should also look for signs of another disorder, polymyalgia rheumatica. These conditions often occur together.

Rheumatoid Arthritis

https://www.niams.nih.gov/health-topics/rheumatoid-arthritis

What is rheumatoid arthritis? Rheumatoid arthritis (RA) is a chronic (long-lasting) disease that mostly affects joints, such as the wrist, hands, feet, spine, knees, and jaw. In joints, RA causes inflammation that leads to: Pain. Swelling Stiffness. Loss of function. Rheumatoid arthritis is an autoimmune disorder because the immune system attacks the healthy joint tissues. Normally, the immune system helps protect the body from infection and disease. RA may cause you to feel unusually tired, to have occasional fevers, and to have a loss of appetite. It also may cause other medical problems in the heart, lungs, blood, nerves, eyes

Fibromyalgia

https://www.niams.nih.gov/health-topics/fibromyalgia

What is fibromyalgia? Fibromyalgia is a long-lasting or chronic disorder that causes muscle pain and fatigue (feeling tired). If you have fibromyalgia, you have pain and tenderness throughout your body. Sometimes you may have two or more chronic pain conditions at the same time, such as: Chronic fatigue syndrome. Endometriosis. Irritable bowel syndrome. Interstitial cystitis. Temporomandibular joint dysfunction (TMJ). Vulvodynia.

Paget’s Disease of Bone

https://www.niams.nih.gov/health-topics/pagets-disease-bone

What is Paget’s disease? Paget’s disease of bone is a chronic (long-lasting) disorder that causes bones to grow larger and become weaker than normal. Usually only one or a few bones have the disease. Many people with Paget’s disease do not have symptoms. However, the bone changes can cause: Bone pain. Misshapen bones. Broken bones (fractures). Problems in the joints near the bones with the disease. With treatment, many people can: Manage their symptoms. Improve pain. Control the effects of the disease.

New rheumatoid arthritis drug targets NIH-discovered protein

https://www.niams.nih.gov/newsroom/press-releases/rheumatoid-arthritis-drug-targets-protein

Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
EmailPrintShare